Navigation Links
MIGENIX Reports First Quarter Fiscal 2009 Financial Results
Date:9/15/2008

-------------------------------------------------

-------------------------------------------------------------------------

STATEMENTS OF CASH FLOWS Three months ended

Unaudited - In Thousands of Canadian dollars July 31,

2008 2007

-----------------------

Loss for the period $ (2,644) $ (3,100)

Items not affecting cash:

Amortization 109 137

Stock-based compensation 181 133

Deferred share units compensation 62 -

Accretion of convertible royalty participation

units and amortization of transaction costs 574 421

Changes in non-cash working capital items

relating to operating activities (236) (13)

-------------------------------------------------------------------------

Cash used in operating activities $ (1,954) $ (2,422)

-------------------------------------------------------------------------

Proceeds on exercise of warrants - 36

-------------------------------------------------------------------------

Cash provided by financing activities $ - $ 36

-------------------------------------------------------------------------

Funds from (purchases of) short-term investments 2,975 6,880

Proceeds on disposal of equipment - 12

Purchases of property and equipment (4) (75)

-------------------------------------------------------------------------

Cash provided by investing activities $ 2,971
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Migenix averts proxy contest; reaches agreement with DJohnson holdings
2. Notice of MIGENIX General Meeting of Shareholders
3. MIGENIX Fourth Quarter and Fiscal Year 2008 Financial Results Conference Call & Webcast Notification
4. MIGENIX Corporate Update and Requisition of Special Meeting
5. Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
6. MIGENIX Appoints Pieter Dorsman to Board of Directors
7. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
8. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
9. MIGENIX releases CEO message #22
10. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
11. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Inc. (Nasdaq: ONXX ) today announced that ... Care Conference on Wednesday, November 12,at 10:00 a.m. ... access a live webcast of the presentation on ... recommended that listeners log on 15 minutes early ...
... In a survey of 100 infectious,disease specialists ... as standing out above other companies at the ... best overall image,in infectious disease. GlaxoSmithKline, Pfizer and ... image among the specialists., The 2008 ICAAC/IDSA ...
... Shire plc,(LSE: SHP, NASDAQ: SHPGY), the global ... all pending litigation in,connection with former dissenting shareholders ... same price of $37 per share originally,offered to ... July 2005 merger, plus,interest., Background to the ...
Cached Biology Technology:According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists 2Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation 2Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation 3
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... is developing a comprehensive data system that can be ... providing them with access to chemical toxicity information. ... building the "automated profiling system" from existing bioassay data ... can help scientists who are seeking information on chemicals ...
... (November 14, 2013)Provocative new research shows that the ... cases of malaria in 2010, may be "rapidly evolving" to ... in millions of Africans, scientists reported today at the annual ... (ASTMH). In large swaths of sub-Saharan ...
... Reserve University and Cleveland Clinic Lerner Research Institute have ... over 100 million cases of malaria annuallychanges that may ... considered resistant, susceptible to infection. Peter A. Zimmerman, ... Case Western Reserve School of Medicine, and David Serre, ...
Cached Biology News:Toxicity database under development at Rutgers-Camden 2New research finds potential risk for millions in Africa believed resistant to vivax malaria 2New research finds potential risk for millions in Africa believed resistant to vivax malaria 3New research finds potential risk for millions in Africa believed resistant to vivax malaria 4Vivax malaria may be evolving around natural defense 2Vivax malaria may be evolving around natural defense 3
...
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
Biology Products: